Eli Lilly’s Zepbound single-dose vials will expand access to more patients: Mizuho’s Jared Holz

August 27, 2024
Eli Lilly’s Zepbound single-dose vials will expand access to more patients: Mizuho’s Jared HolzEli Lilly’s Zepbound single-dose vials will expand access to more patients: Mizuho’s Jared Holz

Jared Holz, Mizuho Securities healthcare equity strategist, joins ‘Squawk Box’ to discuss Eli Lilly’s announcement to release single-dose vials of its anti-obesity drug Zepbound, how the news will expand access to the drug, state of the obesity drug market, and more.

Share This

Latest Mizuho News

Selective opportunities in software stocks amid sell-off, says Mizuho’s Gregg Moskowitz

Selective opportunities in software stocks amid sell-off, says Mizuho’s Gregg Moskowitz

February 17, 2026
Eli Lilly has already won the weight loss drug battle, says Mizuho’s Jared Holz

Eli Lilly has already won the weight loss drug battle, says Mizuho’s Jared Holz

February 23, 2026
Polymarket settling with USDC helped drive our upgrade of Circle, says Mizuho’s Dan Dolev

Polymarket settling with USDC helped drive our upgrade of Circle, says Mizuho’s Dan Dolev

February 25, 2026

Mizuho news from around the globe

back-to-top-blue